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Abstract
Background: The Rearranged during Transfection (RET) protein is overexpressed in a subset of Estrogen Receptor
(ER) positive breast cancer, with both signalling pathways functionally interacting. This cross-talk plays a pivotal role
in the resistance of breast cancer cells to anti-endocrine therapies, and RET expression is assumed to correlate with
poor prognosis based on findings in small patient cohorts. The aim of our study was to investigate the impact of
RET expression on patient outcome in human breast cancer.
Methods: We performed an immunohistochemical analysis of RET protein expression on a tissue microarray
encompassing 990 breast cancer patients and correlated its expression with clinicopathological parameters and
survival data.
Results: Expression of RET was detected in 409 out of 990 cases (41.3%). RET and ER expression significantly
correlated (p < 0.0001). The Luminal B HER2-positive subtype showed the highest expression rate (48.9%). In
univariate and multivariate survival analyses, RET expression had no impact on overall survival.
Conclusion: We confirmed the co-expression of RET and ER, but we did not find RET expression to be an
independent prognostic factor in human breast cancer. Clinical trials with newly developed RET inhibitors are
needed to evaluate if RET inhibition has a beneficial impact on patient survival in ER positive breast cancer.
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Background
The Rearranged during Transfection (RET) protein belongs
to the receptor tyrosine kinase (RTK) superfamily encoded
by the RET gene on the human chromosome 10q11.2 [1]. Li-
gands of the E glial cell line-derived neurotrophic factor
(GDNF) family of growth factors bind to one of four GDNF
family α-receptors (GFRα1–4) leading to RET dimerization
and trans-phosphorylation of intracellular tyrosines [2],
which in turn regulate cellular differentiation, survival, prolif-
eration, migration and chemotaxis [1]. The first causative
oncogenic role of the RET gene was identified in human
papillary thyroid carcinoma (PTC) [3–5]. Moreover, RET
seems to also play a role in many other cancer entities and
cancer syndromes [6–15].
The concept of activated receptor protein kinases in breast
cancer has been well established, as overexpression or ampli-
fication promotes tumour growth [1, 7–10]. With regard to
RET, results have been initially conflicting [11, 12]. However,
RET has been increasingly gaining attention [13], and over-
expression of RET and its coreceptor GFRα1 was demon-
strated in a subset of hormone receptor positive breast
cancers [4]. Moreover, a functional interaction between the
RET and ER signalling pathways has been shown in breast
cancer cell line studies [6, 14]: First, oestrogen stimulation
seems to highly upregulate RET and GFRα mRNA, sug-
gesting that RET and GFRα are direct target genes of
oestrogen signalling [6]. Secondly, RET activation has been
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demonstrated to increase ERα phosphorylation as well as
ER-independent transcriptional activation of ERα target
genes [14], leading to an increased oncogenicity and po-
tentiation of oestrogen-driven proliferation [6].
The molecular mechanisms involved in the cross-talk be-
tween upstream kinases and ERα play a pivotal role in the
resistance to anti-endocrine therapies [1, 14, 15] and RET
expression seems to be associated with disease recurrence
after adjuvant Tamoxifen treatment [14]. An additional
mechanism of RET in endocrine resistance is the inter-
action with inflammatory cytokines. RET expression in-
creases interleukin (IL)-6 levels in the presence of
endocrine treatment, resulting in a positive-feed forward
loop [16]. Due to the important role of IL-6 in breast can-
cer cell migration, RET not only seems to have an impact
on tumour growth but also on metastasis [16, 17].
Supported by the association of RET expression and poor
prognosis [15–17] as well as an association with negative
prognostic factors such as large tumour size [16], the com-
bination of endocrine therapy with agents blocking the
RET signalling pathway could be a possible approach to
overcome endocrine resistance in breast cancer, and has be-
come the subject of preclinical research and various clinical
trials [1, 15, 18, 19]. Several preclinical studies have shown
at least a partial reversibility of endocrine resistance in vivo
and in vitro with RET inhibitors [15, 18–20]. However,
early clinical trials using RET inhibitors alone or in combin-
ation with aromatase inhibitors have struggled with either
high toxicity or lack of benefit [1].
In summary, due to its specific role in endocrine resist-
ance as well as the possible correlation with poor progno-
sis, RET remains a promising therapeutic target in breast
cancer [16]. However, analyses of RET expression and as-
sociation with clinicopathological parameters including
survival data in larger patient cohorts are missing. To fur-
ther investigate the role of RET expression in human
breast cancer we performed an immunohistochemical
analysis on breast cancer tissue microarrays (TMA) with
detailed clinical and survival data. This study is reported
according to the reporting recommendations for tumour
marker prognostic studies (REMARK) [21].
Material and methods
Tissue microarray
Six Tissue Microarrays (TMA) encompassing a total of
1624 breast cancer tissue punches originating from
formalin-fixed and paraffin-embedded tumour tissue were
used and assembled into a TMA format as previously de-
scribed [22, 23]. The specimens derived from patients di-
agnosed with primary breast cancer between 1985 and
2015 (approximately 90% of them between 1985 and
1995) at the Institute of Pathology and the private Insti-
tute Boss and Spichtin, Switzerland. Due to loss of tissue
on individual punches, a total of 990 samples could be
evaluated. The loss of tissue is explained by the fact that
the TMA have already been used multiple times for vari-
ous scientific projects and therefore some of the punches
are depleted. Additionally, not all tissue punches do indeed
contain cancer tissue, but rather benign surrounding tissue,
which could not be included in our analysis. Histopatho-
logical data was obtained from the individual pathology re-
ports while clinical and survival data were extracted from
the hospital database, Cancer Registry of Basel or from the
patients’ attending physicians. Ethical standards and pa-
tients’ confidentiality were ensured and in line with regula-
tions of the local institutional review board (Ethikkomission
Nordwest- und Zentralschweiz, EKNZ 2014–397) and data
safety laws.
Immunohistochemistry
For immunohistochemical staining, 4 μm sections of the
TMA blocks were incubated for 12min with the polyclonal
membranous and cytoplasmatic anti-RET antibody (Clone
ab133710, Abcam, Cambridge, UK) in a dilution of 1:50 after
heat induced antigen retrieval with citrate buffer at pH 6 for
16min. Standard-technique for Benchmark Ultra with opti-
View system was employed. Counterstaining was performed
with hematoxylin solution. For Ki-67 (Clone IR626, Dako,
Santa Clara, CA, USA) immunostaining was performed on
Benchmark Ultra with optiView system. ER, Progesterone
Receptor (PR) and HER2 were stained and scored as previ-
ously described [24]. For 88% of the breast cancer cases, ER,
PR and HER2 were evaluated on the TMA punches, for the
other 12%, these markers were evaluated on whole slide sec-
tions of the donor blocks.
The analysis of RET expression was performed by two
observers (RM and SM), both blinded to the histopatho-
logical, clinical and survival data. The RET expression was
scored as [24]: 0 = absent staining, 1 = weak intensity, 2 =
intermediate intensity, 3 = strong intensity (Fig. 1). For the
statistical analysis, the score was dichotomised into absent
staining and weak intensity (RET negative) versus inter-
mediate and strong intensity (RET positive). Since the
staining was evenly distributed across all tumour cells per
cancer sample, the proportion of stained tumour cells was
not assessed.
Statistical analysis
Statistical analyses for categorical and non-categorical vari-
ables were performed using Fisher’s Exact and -Chi-squared
tests, respectively. Overall survival was calculated using the
Kaplan-Meier method and differences between groups
assessed using log-rank tests. Univariate and multivariate
analyses for overall survival on clinicopathologic parameters
and RET expression were performed using the Cox propor-
tional hazards regression model. Hazard ratios and corre-
sponding 95% confidence intervals were estimated. All tests
were two-sided. P-values < 0.05 were considered statistically
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significant. All analyses were performed using Graphpad
Prism 6.0 (Graphpad Software, Inc., La Jolla, CA), SPSS ver-
sion 20 (IBM, Armonk, NY) or R v3.4.2.
Results
The mean age of all 990 evaluable patients was 64 years
(SD +/− 14) at the time of diagnosis and mean follow up
time was 80.8 months (range 1–263). Most of the tu-
mours (78.4%) were less than 5 cm in diameter (T1-T2),
without lymph node involvement at the time of diagno-
sis (51.3%) and could be allocated to the intrinsic lu-
minal B subtype (53.0%).
The relatively high proportion of luminal B subtype can-
cers in our population could be partly due to the low
threshold of Ki-67at ≥14% and the fact that Ki-67 was eval-
uated on the TMA tissue punches, which does not account
for heterogeneity of Ki-67 distribution and might have led
to an overestimation of Ki-67 expressing cells in some can-
cers. Other than that, there is no obvious explanation for
the high incidence of luminal B subtypes.
Detailed demographic information of the patients can
be found in Table 1.
The expression of RET was significantly associated with
the expression of ER (p < 0.0001, Table 2). No significant as-
sociation of RET expression with tumour size, patient’s age,
tumour grade and AJCC primary tumour staging system
(TNM) such as tumour size (pT) and lymph node involve-
ment (pN) was identified. Moreover, no significant associ-
ation was found between RET expression and the expression
of HER2 as well as the proliferation marker Ki-67 (Table 2).
Looking at the breast cancer intrinsic subtypes as defined by
the St. Gallen consensus conference [25], RET expression
differed significantly between the five subtypes. The lowest
expression was observed in basal-like subtype (31.2%)
followed by HER2 type (36.4%), luminal B subtype
(HER2-negative) (45.3%) and luminal A subtype (46.0%).
Of all intrinsic subtypes, the luminal B HER2-positive sub-
type showed the highest expression rate (48.9%, p = 0.001,
Table 3). In summary, ER expressing subtypes show a
RET expression in 45–46% of cases, while ER-negative
subtypes express RET in only 31–36% of cases.
In the univariate survival analysis, RET expression had no
significant impact on overall survival (OS) of breast cancer
patients (p= 0.87) In particular, subgroup analysis of intrinsic
subtypes revealed no correlation of RET expression with
overall survival (Table 4, Fig. 1). For multivariate analysis, we
adjusted for grade, tumour size (pT) and lymph node status
(pN), age and intrinsic subtypes. We were able to confirm
that age (p < 0.0001), tumour size (pT) (p < 0.0001), lymph
node involvement (pN) (p < 0.0001) and tumour grade (p <
0.0001) were independent prognostic factors and correlated
with worse overall survival. Importantly, RET expression had
no significant impact on overall survival and is thus not a
prognostic factor in human breast cancer in our collective
(p= 0.79, Table 5, Fig. 2).
Discussion
In the present study, we analysed the role of RET expres-
sion in a large cohort of 990 primary breast cancer cases
and correlated the expression with clinicopathological
Fig. 1 Five representative photographs of breast cancer tissue punches with immunohistochemical staining of breast cancer cells for RET a:
absent staining (0), Magnification 200×; b: weak intensity (1+), Magnification 100×; c: weak intensity (1+), Magnification 200×; d: strong intensity
(3+), Magnification 100×; e: strong intensity (3+), Magnification 200×
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parameters and survival data. We were able to demon-
strate a clear correlation of RET expression with ER ex-
pression. Importantly, our data suggests that RET
expression has no impact on overall survival and thus is
not a prognostic factor in human breast cancer.
Since its initial discovery RET has increasingly gained
importance in multiple cancer types including breast
cancer [12, 26–31]. While RET expression in pancreatic
cancer has been consistently reported to correlate with
poor survival [26–28] results regarding survival in breast
cancer are not entirely consistent [16] and only a few re-
ports using human tissue exist. Gatelli et al. [16] exam-
ined RET expression in 89 breast cancer patients. They
could demonstrate a correlation of high RET expression
with larger tumour size as well as with a decreased
metastasis-free and overall survival. Morandi et al. [19]
analysed the RET co-receptor ligand GDNF and its sig-
nalling pathway in a GDNF-response gene set and corre-
lated it to a dataset of 81 ER positive breast cancer
patients as well as 597 breast cancer samples from “The
Table 1 Basic demographic data of all evaluable breast cancer cases (n = 990)
Mean tumour size (mm) ± SD 32 ± 18
Mean age at diagnosis (years) ± SD 64 ± 14
Number Percentage
(n) (%)
Tumour stage
pT1 236 23.8
pT2 541 54.6
pT3 85 8.6
pT4 127 12.8
NA 1 0.2
Lymph node involvement
pN0 508 51.3
pN1 370 37.4
pN2 98 9.9
pN3 8 0.8
NA 6 0.6
Tumour grade
1 206 20.8
2 354 35.8
3 429 43.3
NA 1 0.1
Histologic subtype
Invasive ductal 739 74.6
Invasive lobular 107 10.8
Mucinous 25 2.5
Apocrine 19 1.9
Cribriform 32 3.2
Others 65 6.6
NA 3 0.4
Intrinsic subtype
Luminal A-like (ER+and/or PR+, HER2−, Ki-67 < 14%) 124 12.5
Luminal B-like (HER2-negative) (ER+and/or PR+, HER2−, Ki-67≥ 14%) 435 43.9
Luminal B-like (HER2-positive) (ER+and/or PR+, HER2+) 90 9.1
HER2 type (ER−, PR−, HER2+) 77 7.8
Basal-like (ER−, PR−, HER2−) 260 26.3
NA 4 0.4
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Table 2 Association between RET expression and clinicopathological parameters
Clinicopathologic parameter RET-positive RET-negative p value
Mean tumour size (mm) ± SD 31 ± 17 32 ± 18 0.309
Mean age at diagnosis (years) ± SD 64 ± 14 64 ± 14 0.550
(n) (%) (n) (%)
Tumour stage 0.546
pT1 99 41.9 137 58.1
pT2 224 41.4 317 58.6
pT3 39 45.9 46 54.1
pT4 46 36.2 81 63.8
NA 1 100 0 0
Lymph node involvement 0.468
pN0 201 39.6 307 60.4
pN1 163 44.1 207 55.9
pN2 37 37.8 61 62.2
pN3 4 50.0 4 50.0
NA 4 66.7 2 33.3
Tumour grade 0.401
1 91 44.2 115 55.8
2 137 38.7 217 61.3
3 181 42.2 248 57.8
NA 0 0 1 100
Oestrogen receptor < 0.0001
ER+ 295 46.0 347 54.0
ER− 114 32.8 234 67.2
HER2 0.666
HER2+ 72 43.1 95 56.9
HER2− 337 40.9 486 59.1
Ki67 0.635
Ki67-high 331 41.7 463 58.3
Ki67-low 75 39.5 115 60.5
NA 3 50.0 3 50.0
Table 3 Association between RET expression and breast cancer intrinsic subtype
Intrinsic subtype RET-positive RET-negative p value
(n) (%) (n) (%) 0.001
Luminal A (ER+and/or PR+, HER2−, Ki-67 < 14%) 57 46.0 67 54.0
Luminal B (HER2-negative) (ER+and/or PR+, HER2−, Ki-67≥ 14%) 197 45.3 238 54.7
Luminal B (HER2-positive) (ER+and/or PR+, HER2+) 44 48.9 46 51.1
HER2 type (ER−, PR−, HER2+) 28 36.4 49 63.6
Basal-like (ER−, PR−, HER2−) 81 31.2 179 68.8
NA 2 50.0 2 50.0
Mechera et al. BMC Cancer           (2019) 19:41 Page 5 of 10
Cancer Genome Atlas” [32] Not only did they find a sig-
nificant higher GDNF score in Luminal B breast cancer
subtype in both data sets, but also a decreased distant
metastasis free survival, relapse free survival and overall
survival in this subtype [19]. Together with the fact that
the Luminal B subtype is characterised by poorer prog-
nosis within ER positive breast cancers [33], these results
suggest a correlation of an activated GDNF signalling
cascade resulting in RET activation. Concordantly, we
found high RET expression rates in the Luminal B breast
cancer subtypes. Another study by Griseri et al. [34] per-
formed a RET genotyping association study in a cohort
of 93 ER positive breast cancers and also found a statisti-
cally significant association of RET over-expression with
poor prognosis.
While our data did not confirm an impact of RET ex-
pression on prognosis in ER positive breast cancer, we
were able to reproduce the association of RET and ER
expression [4]. This correlation was underlined in the
past by the discovery of a cross-talk of the RET and ER
signalling cascade [6]. While RET and GFRα seem to be
direct target genes for oestrogen signalling, RET signal-
ling in turn increases ER independent transcriptional ac-
tivation of ERα target genes [6]. Further exploration
revealed that RET plays a significant role in the resistance
of cancer cells to endocrine treatment [1]. By expressing
RET, the tumour cells develop de novo resistance and be-
come resistant after an initial response [7, 14, 15].
Plaza-Menacho et al. [14] have shown that RET downreg-
ulation results in a 6.2-fold increase in sensitivity of the
ER positive MCF7 cell line to the antiproliferative effect of
the selective ER modulator Tamoxifen. Moreover, GDNF
stimulation caused resistance to the drug and targeting
RET restored Tamoxifen resistance [14]. A consecutive
TMA study of 245 primary human breast cancers showed
an association between RET expression and recurrent dis-
ease after adjuvant Tamoxifen treatment [14].
In summary, the crosstalk between RET and ER is im-
portant in the development of endocrine resistance and
specifically targeting RET within combination treatment
regimens might help to restore endocrine resistance in
ER positive tumours. Since a majority (70%) of breast
cancers are ER positive [35], strategies are needed to ad-
dress this therapeutic problem [7, 36].
While specific RET inhibitors are only beginning to
emerge, two different types of inhibitory agents are cur-
rently evaluated within preclinical and clinical trials in
breast cancer [1]. Small molecule tyrosine kinase inhibi-
tors are therapeutic substances, which are not exclu-
sively targeting RET but also other tyrosine kinases [37].
Some of them at least partially managed to overcome
endocrine resistance in breast cancer cell lines and
mouse models [15, 18–20]. However, clinical Phase I
and II studies struggle with a lack of benefit or toxicity
when using such inhibitors, for example Sorafenib, Ima-
tinib or Sunitinib, as monotherapies [38–41]. Combin-
ation therapy of Sorafenib with endocrine therapy as
well as Sunitinib with chemotherapy showed more
promising results but further data is needed [42]. Vaden-
tanib monotherapy as well as its use within combination
Table 4 Univariate analyses for all cases, and by intrinsic subtype, for the effect of RET expression on overall survival
RET expression, all cases Hazard Ratio (95% CI) p value
RET positivity 1.02 (0.82–1.26) 0.87
RET positivity, by intrinsic subtype
Luminal A (ER+and/or PR+, HER2−, Ki-67 < 14%) 1.54 (0.79–3.00) 0.21
Luminal B (HER2-negative) (ER+and/or PR+, HER2−, Ki-67 ≥ 14%) 0.99 (0.72–1.36) 0.95
Luminal B (HER2-positive) (ER+and/or PR+, HER2+) 1.00 (0.52–1.95) 0.99
HER2 type (ER−, PR−, HER2+) 1.46 (0.73–2.92) 0.28
Basal-like (ER−, PR−, HER2−) 0.86 (0.54–1.37) 0.52
RET positivity, by ER status
ER+ 1.06 (0.82–1.38) 0.65
ER− 1.05 (0.72–1.52) 0.81
Table 5 Multivariate analysis for the effect of clinicopathologic
parameters and RET expression on overall survival
Clinicopathologic parameter Hazard Ratio (95% CI) p-value
Age (per 1-year) 1.04 (1.03–1.05) < 0.0001
Tumour size (pT) 1.29 (1.14–1.45) < 0.0001
Lymph node involvement (pN) 1.47 (1.25–1.73) < 0.0001
Tumour grade (BRE) 1.77 (1.50–2.10) < 0.0001
Intrinsic subtype
Luminal A 1
Luminal B (HER2-negative) 0.96 (0.66–1.39) 0.81
Luminal B (HER2-positive) 1.03 (0.64–1.65) 0.92
HER 2 type 0.86 (0.51–1.45) 0.58
Basal-like 1.43 (0.94–2.18) 0.09
RET expression
RET-positive 1.03 (0.83–1.28) 0.79
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schemes was well tolerated but failed to demonstrate im-
proved survival [43]. Several clinical trials are ongoing [1].
However, none of these drugs have been approved for a co-
hort with an actionable alteration involving RET [44], stres-
sing the importance of defining patients who might benefit
from RET inhibition.
Recent studies identified more specific and potent
RET inhibitors such as Sitravatinib, which are currently
evaluated in thyroid and non-small cell lung cancer [44,
45]. These trials will hopefully enlighten the debate
about their potential benefits and show a reduced
toxicity.
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Fig. 2 a: Kaplan–Meier survival curve for overall survival depending on the expression of RET (univariate analysis); b–f: Kaplan–Meier survival
curves for overall survival depending on the expression of RET for the indicated breast cancer intrinsic subtypes
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While the results of small molecule tyrosine inhibitors are
difficult to interpret, inhibition of RET downstream signal-
ling elements, shared with other signalling pathways [14],
seem to be currently more promising. The ER receptor con-
tains two transcription active domains, activation function
(AF)-1 and AF-2 [7]. While AF-2 activity is dependent on es-
trogen binding, AF-1 is regulated by phosphorylation medi-
ated via extracellular signal–regulated kinases (ERK) 1/2,
phosphatidylinositol 3-kinase (PI3K)/AKT, Protein kinase
cAMP-dependent (PKA), cyclin A/E-CDK2, P21-Activated
Kinase (PAK)1, cyclin-dependent kinase (CDK)7/Transcrip-
tion factor II Human (TFIIH), p90RSK or p38 pathways.
These are activated themselves by a large number of receptor
tyrosine kinases including several growth factor receptor
families [1, 7]. The activation of RET by GDNF in this con-
text, has been demonstrated to increase ERα phosphoryl-
ation and estrogen-independent transcriptional activation of
ERα target genes [14]. Interestingly, the RET downstream
signalling in GDNF-treated MCF7 cells happens to a
higher extent via the mechanistic target of Rapamycin
(mTOR)/p70S6K pathway than the ERK1/2 and PI3K/
AKT pathway [14]. This is confirmed by the fact, that
RET downstream signalling was blocked with mTOR in-
hibitor Rapamycin, while a chemical inhibition of AKT
and ERK1/2 had no impact [14]. By adding the mTOR in-
hibitor Everolimus to an aromatase inhibitor the BO-
LERO2 trial, managed to show an improved median
progression-free survival of 6months in ER positive breast
cancer [46]. Therefore, current evidence suggests down-
stream elements of RET as possible therapeutic targets.
A general limitation of our study is that older samples
might have suffered from loss of protein antigenicity,
which might have affected the immunohistochemical
staining outcome. A further point which needs to be
mentioned is the method of defining the molecular sub-
types. We used the definition of the St. Gallen Consensus
Conference, which only provide an approximate definition of
intrinsic subtypes and might lead to a underestimation of the
impact of RET in the triple negative subtype [25, 47]. An-
other limiting factor is related to the follow-up in this study.
Luminal A subtypes and T1/2N0 stage cancers have a less
aggressive course of disease and might recur even after 10
years. These late recurrences might therefore not be repre-
sented in our study due to the mean follow up period of 6.7
years.
A final limiting fact is the long recruitment period of
31 years which might have affected definitions of histo-
pathological grading and staging. The same accounts for
changing treatment regimens over time, which could
have influenced the survival data.
Conclusion
In summary, the results of our study confirm current know-
ledge that RET is an important element in ER positive breast
cancer. However, our results, derived from a large breast
cancer patient cohort with annotated clinicopathological
data, underline the uncertainty regarding the prognostic im-
pact of RET expression on patient survival in breast cancer
and stresses the importance of further research. In light of
this, further clinical trials identifying an adequate patient
subgroup which might profit from RET inhibition as well as
further studies investigating the impact of RET expression
on patient outcome in breast cancer are clearly needed.
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